Current Opinion in Rheumatology

Article	Citations
COVID-19 and autoimmune diseases	319
The role of diet in hyperuricemia and gout	57
Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate	51
Recent advances in targeted drug delivery for treatment of osteoarthritis	43
Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases	42
Antirheumatic medications in pregnancy and breastfeeding	39
Management issues in rheumatoid arthritis-associated interstitial lung disease	38
Management of systemic sclerosis: the first five years	36
Racial, ethnic, and healthcare disparities in rheumatoid arthritis	36
Preclinical rheumatoid arthritis and rheumatoid arthritis prevention	34
The role of CD8+ T-cell systemic lupus erythematosus pathogenesis: an update	34
Double-negative T cells in autoimmune diseases	33
Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications	33
Benefits and promotion of physical activity in rheumatoid arthritis	33
Osteoporosis and fractures in rheumatoid arthritis	32
Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus	32
COVID-19 and rheumatoid arthritis	31
Systemic sclerosis pathogenesis: contribution of recent advances in genetics	30
Immune mechanisms of fibrosis and inflammation in IgG4-related disease	28
Blood and urine biomarkers in osteoarthritis – an update on cartilage associated type II collagen and aggrecan markers	28
Telerheumatology: before, during, and after a global pandemic	28
The metabolic signature of T cells in rheumatoid arthritis	28
Treatment for systemic sclerosis-associated interstitial lung disease	27
Cellular aspects of the pathogenesis of lupus nephritis	25
Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases	25

The association of Behçet's syndrome with HLA-B51 as understood in 2021	23
Lyme disease: diagnosis and treatment	22
Comorbidities in gout and hyperuricemia: causality or epiphenomena?	22
Update on noninfectious uveitis in children and its treatment	22
Role of adipose tissues in osteoarthritis	22
Recent advances in the diagnosis and management of giant cell arteritis	22
Interstitial lung disease throughout the rheumatoid arthritis disease course	21
Scleroderma epidemiology update	20
Treatment of cutaneous lupus erythematosus: current approaches and future strategies	20
Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis	20
Lymphocyte immunophenotyping in inflammatory myositis: a review	20
Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy	19
Rural health issues in rheumatology: a review	19
New classification criteria for systemic lupus erythematosus	19
Inhalants other than personal cigarette smoking and risk for developing rheumatoid arthritis	19
New galaxies in the universe of shared decision-making and rheumatoid arthritis	18
The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis	18
Osteoporosis epidemiology using international cohorts	18
B cells in systemic lupus erythematosus	17
Update on antimalarials and systemic lupus erythematosus	17
Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology	17
Nonimmune mechanisms in idiopathic inflammatory myopathies	16
Treatment of immune checkpoint inhibitor-induced inflammatory arthritis	16
Cytokines and inflammatory mediators as promising markers of polymyositis/dermatomyositis	16
Future use of musculoskeletal ultrasonography and magnetic resonance imaging in rheumatoid arthritis	16
Physical therapy in axial spondyloarthritis: guidelines, evidence and clinical practice	16
Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights	15
Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies	14
Diagnostic delay in axial spondyloarthritis – a past or current problem?	14
Update in familial Mediterranean fever	14
Ribosome dysfunction in osteoarthritis	14
The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?	14
Update on gout management: what is old and what is new	14
Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis	14
Metabolic control of T cells in autoimmunity	13
Insights into the molecular landscape of osteoarthritis in human tissues	13
Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells	13
Skeletal muscle disease in rheumatoid arthritis: the center of cardiometabolic comorbidities?	13
Pathogenesis of inclusion body myositis	13
Did COVID-19 impact osteoarthritis – clinical perspective?	12
Posttraumatic osteoarthritis: what have we learned to advance osteoarthritis?	12
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment	12
Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance	12
Therapeutic advances in eosinophilic granulomatosis with polyangiitis	12
Polymyositis: does it really exist as a distinct clinical subset?	12
Calcinosis in systemic sclerosis	11
Low-dose computed tomography for axial spondyloarthritis: update on use and limitations	11
Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis	11
Novel classifications for systemic sclerosis: challenging historical subsets to unlock new doors	11
MRI of the sacroiliac joints: what is and what is not sacroiliitis?	11

MHC class I associations beyond HLA-B27: the peptide binding hypothesis of psoriatic arthritis and its implications for disease pathogenesis	11
Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment	11
Differential diagnosis of necrotizing myopathy	11
Immunometabolism in the pathogenesis of systemic lupus erythematosus: an update	11
Immunopathogenesis of skin injury in systemic lupus erythematosus	10
Autoimmunity and immunodeficiency	10
Janus kinase–signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition	10
Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit	10
Monitoring disease activity and damage in adult and juvenile idiopathic inflammatory myopathy	10
Inflammation in osteoarthritis: the latest progress and ongoing challenges	10
Up-to-date treatment and management of myositis	10
Cutaneous and systemic connections in lupus	10
Anti-HMGCR myopathy: clinical and histopathological features, and prognosis	10
Cancer and scleroderma: recent insights	10
Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible?	9
Is osteoarthritis a mitochondrial disease? What is the evidence	9
The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy	9
Review of publications evaluating opioid use in patients with inflammatory rheumatic disease	9
Takayasu arteritis	9
The transition from enthesis physiological responses in health to aberrant responses that underpin spondyloarthritis mechanisms	9
Spondyloarthritis evolution: what is in your history?	9
Update on the cellular pathogenesis of lupus	9
Cardiac involvement in inflammatory myopathies and inherited muscle diseases	9
Raynaud's phenomenon and digital ulcers: advances in evaluation and management	9
Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus	9
Glucocorticoid and opioid use in rheumatoid arthritis management	9
Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence	9
Integrating genetic and social factors to understand health disparities in lupus	9
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic	8
Treatment of thrombotic antiphospholipid syndrome in adults and children	8
The use of mycophenolate mofetil area under the curve	8
Anti-MDA5 dermatomyositis: an update from bench to bedside	8
A cursed goodbye kiss from severe acute respiratory syndrome-coronavirus-2 to its pediatric hosts: multisystem inflammatory syndrome in children	8
Biologic therapies for systemic lupus erythematosus: where are we now?	8
New lupus criteria: a critical view	8
Myositis autoantibodies: recent perspectives	8
Intestinal dysbiosis in spondyloarthritis – chicken or egg?	7
Fibromyalgia and centralized pain in the rheumatoid arthritis patient	7
Scleroderma autoantibodies in guiding monitoring and treatment decisions	7
Gout and the COVID-19 pandemic	7
Haematopoietic stem cell transplantation in paediatric rheumatic disease	7
Advances in osteoarthritis imaging	7
Role of cellular senescence in the pathogenesis of systemic sclerosis	7
An update on the microbiome in vasculitis	7
Role of Janus Kinase inhibitors in rheumatoid arthritis treatment	7
Barrier lymphocytes in spondyloarthritis	6
Healthcare disparities in telemedicine for rheumatology care	6
A treat-to-target approach is needed for Behçet's syndrome	6
Role for antimalarials in the management of COVID-19	6
New mechanism-based approaches to treating and evaluating the vasculopathy of scleroderma	6
Aortitis: an update	6
Insights into origins and specificities of autoantibodies in systemic sclerosis	6
Imaging techniques for assessment of vascular involvement in systemic sclerosis	6
Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease	6
Comparing children and adults with chronic nonbacterial osteomyelitis	6
Novel imaging techniques for sacroiliac joint assessment	6
Tackling global challenges in pediatric rheumatology	5
Bone in osteoarthritis: imaging and interventions	5
Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus	5
Dual-energy computed tomography in crystalline arthritis: knowns and unknowns	5
Metabolic perturbations in systemic sclerosis	5
An update on autoantibodies in systemic lupus erythematosus	5
Coronavirus 2019: clinical and neuropathological aspects	5
Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis	5
Osteoarthritis gene therapy in 2022	5
Challenges of caring for transgender and gender diverse patients with rheumatic disease: presentation of seven patients and review of the literature	5
New therapeutic approaches in systemic lupus erythematosus	5
Adherence to gout guidelines: where do we stand?	4
Patient reported outcomes in systemic vasculitis	4
Adipose tissue and adipose secretome in systemic sclerosis	4
How can ultrasonography help in the management of CPPD? From diagnosis to clinical subset identification	4
The role of immunomodulatory medications in the treatment of COVID-19	4
Quo vadis reactive arthritis?	4
The management of enthesitis in clinical practice	4
Updates in cutaneous manifestations of systemic vasculitis	4
Progresses in the imaging of calcium pyrophosphate crystal disease	4
Biomarkers of disease activity in dermatomyositis	4
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria sets for three types of antineutrophilic cytoplasmic antibody-associated vasculitis	4
Optimizing reproductive health management in lupus and Sjogren's syndrome	4
Is it time to move on from pelvic radiography as the first-line imaging modality for suspected sacroiliitis?	4

Not all benign: disease course, complications, and sequalae of chronic recurrent multifocal osteomyelitis in children	4
Treatment of juvenile localized scleroderma: current recommendations, response factors, and potential alternative treatments	4
Recent advances in elucidating the genetic basis of systemic sclerosis	4
Insights into the pathogenic role of neutrophils in systemic lupus erythematosus	4
Clinical features of multisystem inflammatory syndrome in children	4
Sex differences in disease activity and efficacy of treatment in spondyloarthritis: is body composition the cause?	4
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence	4
Uveitis in Behçet disease - an update	4